EXEL News and Press, Exelixis Inc. From 10/08/21

Drug development company Aeterna Zentaris (AEZS), specialized in oncology and endocrine, has made significant advancements in areas of unmet medical needs. But since its therapeutic and diagnostic products are still in their clinical and preclinical development stages, commercialization could...

Predictive Oncology, a precision medicine company focused on applying artificial intelligence to develop personalized medical treatments, has gained significant investor attention because of its potential to expand its unique services to cater to its customers and researchers exploring new ca...

Exelixis' climb to stardom began with a strong Cabometyx first-line presence in renal cell carcinoma, but soon dwindled due to the arrival of immunotherapy. Exelixis was pushed back to second line. However, since achieving approval in January, in combination with immunotherapeutic Opd...

– At a median follow-up of 10.1 months, median progression-free survival was 11.0 months for CABOMETYX compared with 1.9 months for placebo – – Results served as a basis for the recent U.S. FDA approval of CABOMETYX for adult and pediatric patients 1...

– New results for cabozantinib in combination with atezolizumab demonstrate a median progression-free survival in high-risk patients of 6.8 months as assessed by Blinded Independent Radiology Committee – Exelixis, Inc. (Nasdaq: EXEL) today announced det...

– FDA approval based on phase 3 COSMIC-311 pivotal trial, which demonstrated significant improvement in progression-free survival with CABOMETYX versus placebo – – Exelixis is prepared to fully support expanded indication immediately – ...

– Progression-free survival and objective response rate benefits were observed with combination regimen versus sunitinib regardless of prior nephrectomy status – Exelixis, Inc. (Nasdaq: EXEL) today announced results demonstrating efficacy benefits regar...

September has historically been one of the worst months for the stock market. But for investors focused on the long term, this only means that if history repeats itself, we will come across shares of excellent companies trading for a discount in the next few weeks. If you aren't willing...

Exelixis, Inc. (Nasdaq: EXEL) today announced that Gisela M. Schwab, M.D., the company’s President, Product Development and Medical Affairs and Chief Medical Officer, passed away over the weekend. Dr. Schwab had been on a medical leave of absence since June 18, 2021. Exel...

While Precipio (PRPO) is a lesser-known company in the diagnostics and research industry, it generated significant market buzz in May 2021 when its COVID-19 antibody test became available on Amazon’s (AMZN) platform. However, can the stock continue to advance by relying on the antibody...